1998
INCIDENCE AND CLINICAL SIGNIFICANCE OF FALSE-NEGATIVE SEXTANT PROSTATE BIOPSIES
RABBANI F, STROUMBAKIS N, KAVA B, COOKSON M, FAIR W. INCIDENCE AND CLINICAL SIGNIFICANCE OF FALSE-NEGATIVE SEXTANT PROSTATE BIOPSIES. Journal Of Urology 1998, 159: 1247-1250. PMID: 9507846, DOI: 10.1016/s0022-5347(01)63574-2.Peer-Reviewed Original ResearchConceptsSextant prostate biopsyFalse-negative biopsiesProstate biopsyClinical significancePathological parametersRadical prostatectomyRelapse-free survival rateNeoadjuvant hormonal therapyInitial clinical stagePositive repeat biopsyHormonal therapyMost patientsPatients 27Relapse rateRepeat biopsyClinical parametersClinical stageSextant biopsyTrue incidenceTreatment modalitiesSignificant cancerProstate cancerHigh incidenceBiopsySurvival rateINCIDENCE AND CLINICAL SIGNIFICANCE OF FALSE-NEGATIVE SEXTANT PROSTATE BIOPSIES
RABBANI F, STROUMBAKIS N, KAVA B, COOKSON M, FAIR W. INCIDENCE AND CLINICAL SIGNIFICANCE OF FALSE-NEGATIVE SEXTANT PROSTATE BIOPSIES. Journal Of Urology 1998, 159: 1247-1250.. DOI: 10.1097/00005392-199804000-00047.Peer-Reviewed Original ResearchSextant prostate biopsyFalse-negative biopsiesProstate biopsyClinical significancePathological parametersRadical prostatectomyRelapse-free survival rateNeoadjuvant hormonal therapyInitial clinical stagePositive repeat biopsyHormonal therapyMost patientsPatients 27Relapse rateRepeat biopsyClinical parametersClinical stageSextant biopsyTrue incidenceTreatment modalitiesSignificant cancerProstate cancerHigh incidenceAbstract PurposeBiopsy
1997
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
Fair W, Cookson M, Stroumbakis N, Cohen D, Aprikian A, Wang Y, Russo P, Soloway S, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg C, Heston W, Reuter V. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997, 49: 46-55. PMID: 9123736, DOI: 10.1016/s0090-4295(97)00169-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyMargin-positive rateADT groupPathologic stagingRadical prostatectomyProstatic cancerMonths of ADTControl groupNeoadjuvant androgen deprivation therapyPreoperative androgen deprivation therapyDisease-free survival ratesDisease-free rateMonths of goserelinNeoadjuvant androgen deprivationPSA failure ratesPhase II studySubset of patientsAdditional therapeutic interventionsArea of oncologyDefinitive surgeryDeprivation therapyNeoadjuvant chemotherapyPSA failureBiochemical failureControl patients